Key result
Bariatric arterial embolization is a safe, minimally invasive intervention that achieves modest short-term weight loss of 5-12% at 12 months by suppressing ghrelin production.
Why the study?
Traditional interventions for obesity face limitations in effectiveness, accessibility, and patient acceptance, prompting evaluation of bariatric arterial embolization as a minimally invasive alternative.
Does bariatric arterial embolization reduce weight and suppress ghrelin in patients with obesity?
Does bariatric arterial embolization reduce weight and suppress ghrelin in patients with obesity?
Bariatric arterial embolization is a promising, minimally invasive, hormonally targeted intervention that provides modest short-term weight loss and metabolic improvement for obesity management.
BAE merits evaluation as an endovascular obesity option; leaves open efficacy and safety pending randomized trials.
Obesity remains one of the most pressing global health challenges, contributing to significant metabolic, cardiovascular, and psychosocial burdens. Traditional interventions such as diet modification, pharmacologic therapy, and bariatric surgery often face limitations in effectiveness, accessibility, and patient acceptance. This qualitative narrative review examines bariatric arterial embolization (BAE), a minimally invasive endovascular technique that targets the gastric fundus to suppress ghrelin secretion and promote appetite regulation. By reducing hormonal drive to eat, BAE aims to achieve weight loss through physiological modulation rather than anatomical alteration. Evidence from clinical studies demonstrates that BAE produces meaningful short-term weight reduction. The procedure is generally well-tolerated, with transient abdominal discomfort and nausea being the most frequent minor side effects, and serious complications remaining uncommon. Compared to surgical approaches, BAE offers lower procedural risk, faster recovery, and broader applicability for patients seeking non-surgical solutions; however, its long-term durability and metabolic sustainability require further investigation. Overall, this review highlights BAE as a promising addition to the continuum of obesity management, bridging the gap between conservative and surgical interventions. Its minimally invasive, hormonally driven mechanism provides a feasible pathway for weight control and metabolic improvement, underscoring the need for continued research into standardized techniques, patient selection criteria, and long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Salib et al. (2025) conducted a review in Obesity. Bariatric arterial embolization vs. Traditional bariatric surgery or conservative management was evaluated. Bariatric arterial embolization is a safe, minimally invasive intervention that achieves modest short-term weight loss of 5-12% at 12 months by suppressing ghrelin production.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: